Literature DB >> 18763216

Drug discovery and development for Huntington's disease - an orphan indication with high medical need.

Freddy Heitz1, Salvatore La Rosa, Eduardo Gonzalez-Couto, Giovanni Gaviraghi, Georg C Terstappen.   

Abstract

Huntington's disease (HD) is a rare neurodegenerative disorder that progressively destroys the mental capacity and motor control of patients. This loss of motor control results in abnormal body movements (chorea) - the hallmark of HD. Given that no disease-modifying therapy for HD exists and that available symptomatic treatments are not highly efficacious, the medical need for this 'orphan' disease remains high. The number of compounds that are undergoing discovery and development for the treatment of HD has increased significantly in recent years, spurred by legislative incentives for orphan drug development and by support from non-profit foundations. Thus, hope exists for patients with HD that efficacious medicines will become available.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18763216

Source DB:  PubMed          Journal:  IDrugs        ISSN: 1369-7056


  1 in total

1.  Fused 3-Hydroxy-3-trifluoromethylpyrazoles Inhibit Mutant Huntingtin Toxicity.

Authors:  Salvatore La Rosa; Tiziana Benicchi; Laura Bettinetti; Ilaria Ceccarelli; Enrica Diodato; Cesare Federico; Pasquale Fiengo; Davide Franceschini; Ozgun Gokce; Freddy Heitz; Giulia Lazzeroni; Ruth Luthi-Carter; Letizia Magnoni; Vincenzo Miragliotta; Carla Scali; Michela Valacchi
Journal:  ACS Med Chem Lett       Date:  2013-08-08       Impact factor: 4.345

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.